ScholarIQanswers from OpenAlex & ORCID
Nabil F. Saba
ResearcherPublications, citations & collaboration network
Nabil F. Saba is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Nabil F. Saba have?
ScholarIQindexed works
Nabil F. Saba has 824 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Nabil F. Saba have?
ScholarIQcitation count
Nabil F. Saba has 22,089 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Nabil F. Saba?
ScholarIQh-index
Nabil F. Saba has an h-index of 62 in OpenAlex.
What is the i10-index of Nabil F. Saba?
ScholarIQi10-index
Nabil F. Saba has an i10-index of 281 in OpenAlex.
What is the ORCID of Nabil F. Saba?
ScholarIQorcid
The ORCID for Nabil F. Saba is on the source record.
What is the OpenAlex record for Nabil F. Saba?
ScholarIQopenalex
The OpenAlex for Nabil F. Saba is on the source record.
What are the most-cited papers on Nabil F. Saba?
ScholarIQmost cited works
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, J. Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, William J. Geese, Justin Kopit, James W. Shaw, Maura L. Gillison
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, J. Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Mark Lynch, Vijayvel Jayaprakash, Li Li, Maura L. Gillison
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml, Tanguy Y. Seiwert, David G. Pfister, Francis P. Worden, Stephen V. Liu, Jill Gilbert, Nabil F. Saba, Jared Weiss, Lori J. Wirth, Ammar Sukari, Hyunseok Kang, Michael K. Gibson, Erminia Massarelli, Steven Powell, Amy Meister, Xinxin Shu, Jonathan D. Cheng, Robert I. Haddad
Management of locally recurrent nasopharyngeal carcinoma
Anne W.M. Lee, Wai Tong Ng, Jimmy Yu Wai Chan, June Corry, Antti Mäkitie, William M. Mendenhall, Alessandra Rinaldo, Juan P. Rodrigo, Nabil F. Saba, Primož Strojan, Carlos Suárez, Jan B. Vermorken, Sue S. Yom, Alfio Ferlito